These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24059459)

  • 1. Repurposed drugs in metabolic disorders.
    Finsterer J; Frank M
    Curr Top Med Chem; 2013; 13(18):2386-94. PubMed ID: 24059459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Filling the gap in CNS drug development: evaluation of the role of drug repurposing.
    Caban A; Pisarczyk K; Kopacz K; Kapuśniak A; Toumi M; Rémuzat C; Kornfeld A
    J Mark Access Health Policy; 2017; 5(1):1299833. PubMed ID: 28473889
    [No Abstract]   [Full Text] [Related]  

  • 3. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.
    Cummings JL; Zhong K
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):161-5. PubMed ID: 24502586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing drugs targeting metabolic diseases for cancer therapeutics.
    Pillai U J; Ray A; Maan M; Dutta M
    Drug Discov Today; 2023 Sep; 28(9):103684. PubMed ID: 37379903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K; Coté TR
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug repurposing for metabolic disorders: Scientific, technological and economic issues.
    Bui NL; Hoang DA; Ho QA; Nguyen Thi TN; Singh V; Chu DT
    Prog Mol Biol Transl Sci; 2024; 207():321-336. PubMed ID: 38942542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human-based multi-gene signature enables quantitative drug repurposing for metabolic disease.
    Timmons JA; Anighoro A; Brogan RJ; Stahl J; Wahlestedt C; Farquhar DG; Taylor-King J; Volmar CH; Kraus WE; Phillips SM
    Elife; 2022 Jan; 11():. PubMed ID: 35037854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tackling Alzheimer's Disease with Existing Drugs: A Promising Strategy for Bypassing Obstacles.
    Rampa A; Gobbi S; Belluti F; Bisi A
    Curr Med Chem; 2021; 28(12):2305-2327. PubMed ID: 32867634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug repurposing in rare diseases: Myths and reality.
    Fetro C; Scherman D
    Therapie; 2020 Apr; 75(2):157-160. PubMed ID: 32241561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Repurposing in the Development of Anticancer Agents.
    Olgen S; Kotra LP
    Curr Med Chem; 2019; 26(28):5410-5427. PubMed ID: 30009698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing.
    Madugula SS; John L; Nagamani S; Gaur AS; Poroikov VV; Sastry GN
    Comput Biol Med; 2021 Nov; 138():104856. PubMed ID: 34555571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Old wine in new bottles: Drug repurposing in oncology.
    Antoszczak M; Markowska A; Markowska J; Huczyński A
    Eur J Pharmacol; 2020 Jan; 866():172784. PubMed ID: 31730760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in the Development of Pharmaceutical Agents for Metabolic Disorders: A Computational Perspective.
    Janardhan S; Dubovskaja V; Lagunin A; Rao BV; Sastry GN; Poroikov V
    Curr Med Chem; 2018; 25(39):5432-5463. PubMed ID: 28969540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory considerations and intellectual property rights of repurposed drugs.
    Afzaal H; Waseem T; Saeed A; Noori FA; Obaidullah ; Babar MM
    Prog Mol Biol Transl Sci; 2024; 205():357-375. PubMed ID: 38789186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants.
    Trombetta RP; Dunman PM; Schwarz EM; Kates SL; Awad HA
    mSphere; 2018 Oct; 3(5):. PubMed ID: 30381352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions.
    Polamreddy P; Gattu N
    Drug Discov Today; 2019 Mar; 24(3):789-795. PubMed ID: 30513339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs.
    Bhattarai D; Singh S; Jang Y; Hyeon Han S; Lee K; Choi Y
    Curr Top Med Chem; 2016; 16(19):2156-68. PubMed ID: 26881715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Creating New Economic Incentives for Repurposing Generic Drugs for Unsolved Diseases Using Social Finance.
    Bloom BE
    Assay Drug Dev Technol; 2015 Dec; 13(10):606-11. PubMed ID: 26284286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.